Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Incretin-based therapy for type 2 diabetes mellitus: pancreatic and extrapancreatic effects.

Hartman I, Rojas E, Rodríguez-Molina D.

Am J Ther. 2013 Jul-Aug;20(4):384-93. doi: 10.1097/MJT.0b013e318235f27d.

PMID:
23459193
2.

Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.

Kissow H, Hartmann B, Holst JJ, Viby NE, Hansen LS, Rosenkilde MM, Hare KJ, Poulsen SS.

Regul Pept. 2012 Nov 10;179(1-3):91-100. doi: 10.1016/j.regpep.2012.08.016. Epub 2012 Sep 15.

PMID:
22989472
3.

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Jellinger PS.

Postgrad Med. 2011 Jan;123(1):53-65. doi: 10.3810/pgm.2011.01.2245. Review.

PMID:
21293084
4.

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Neumiller JJ.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. Review.

PMID:
19801361
5.

The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.

Morales J.

Postgrad Med. 2011 Nov;123(6):189-201. doi: 10.3810/pgm.2011.11.2508. Erratum in: Postgrad Med. 2012 Jan;124(1):177-8.

PMID:
22104467
6.

The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.

Moon HS, Kim MK, Son MH.

Arch Pharm Res. 2011 Jul;34(7):1041-3. doi: 10.1007/s12272-011-0721-z. Review.

PMID:
21811909
7.

Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.

Verspohl EJ.

Pharmacol Ther. 2009 Oct;124(1):113-38. doi: 10.1016/j.pharmthera.2009.06.002. Epub 2009 Jun 21. Review.

PMID:
19545590
8.

Liraglutide: the therapeutic promise from animal models.

Knudsen LB.

Int J Clin Pract Suppl. 2010 Oct;(167):4-11. doi: 10.1111/j.1742-1241.2010.02499.x. Review.

PMID:
20887299
9.
10.

Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.

Davies M, Speight J.

Diabetes Obes Metab. 2012 Oct;14(10):882-92. doi: 10.1111/j.1463-1326.2012.01595.x. Epub 2012 Apr 17. Review.

PMID:
22420869
11.

On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice.

Rosol TJ.

Toxicol Pathol. 2013 Feb;41(2):303-9. doi: 10.1177/0192623312472402.

PMID:
23471186
12.

Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.

Gallwitz B.

Drugs. 2011 Sep 10;71(13):1675-88. doi: 10.2165/11592810-000000000-00000. Review.

PMID:
21902291
13.

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.

Russell S.

Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22. Review.

PMID:
23263796
14.

The effects of glucagon-like peptide-1 on the beta cell.

Vilsbøll T.

Diabetes Obes Metab. 2009 Dec;11 Suppl 3:11-8. doi: 10.1111/j.1463-1326.2009.01073.x. Review.

PMID:
19878257
15.

Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.

Holst JJ.

Expert Opin Emerg Drugs. 2004 May;9(1):155-66. Review.

PMID:
15155141
16.

Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.

van Genugten RE, van Raalte DH, Diamant M.

Diabetes Res Clin Pract. 2009 Dec;86 Suppl 1:S26-34. doi: 10.1016/S0168-8227(09)70006-3.

PMID:
20115929
17.

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.

Vergès B, Bonnard C, Renard E.

Diabetes Metab. 2011 Dec;37(6):477-88. doi: 10.1016/j.diabet.2011.07.001. Epub 2011 Aug 25. Review.

PMID:
21871831
18.

Emerging GLP-1 receptor agonists.

Lund A, Knop FK, Vilsbøll T.

Expert Opin Emerg Drugs. 2011 Dec;16(4):607-18. doi: 10.1517/14728214.2011.616493. Epub 2011 Sep 9. Review.

PMID:
21905764
19.

Incretin hormone mimetics and analogues in diabetes therapeutics.

Green BD, Flatt PR.

Best Pract Res Clin Endocrinol Metab. 2007 Dec;21(4):497-516. Review.

PMID:
18054732
20.

The future of incretin-based therapy: novel avenues--novel targets.

Ahrén B.

Diabetes Obes Metab. 2011 Oct;13 Suppl 1:158-66. doi: 10.1111/j.1463-1326.2011.01457.x. Review.

PMID:
21824270

Supplemental Content

Support Center